Inhibition of the p66/p51 form of human immunodeficiency virus reverse transcriptase by tRNA(Lys).
Identifieur interne : 002864 ( PubMed/Checkpoint ); précédent : 002863; suivant : 002865Inhibition of the p66/p51 form of human immunodeficiency virus reverse transcriptase by tRNA(Lys).
Auteurs : B. Bordier [France] ; L. Tarrago-Litvak ; M L Sallafranque-Andreola ; D. Robert ; D. Tharaud ; M. Fournier ; P J Barr ; S. Litvak ; L. Sarih-CottinSource :
- Nucleic acids research [ 0305-1048 ] ; 1990.
Descripteurs français
- KwdFr :
- ADN (biosynthèse), ARN de transfert de la lysine (pharmacologie), ARN de transfert de la phénylalanine (pharmacologie), ARN de transfert du tryptophane (pharmacologie), ARN de transfert spécifiques des différents acides aminés (pharmacologie), DNA polymerase II (antagonistes et inhibiteurs), Données de séquences moléculaires, Inhibiteurs de la transcriptase inverse, Pancreatic ribonuclease (pharmacologie), Protéines recombinantes, Ribonuclease T1 (pharmacologie), Séquence nucléotidique, VIH (Virus de l'Immunodéficience Humaine) (enzymologie).
- MESH :
- antagonistes et inhibiteurs : DNA polymerase II.
- biosynthèse : ADN.
- enzymologie : VIH (Virus de l'Immunodéficience Humaine).
- pharmacologie : ARN de transfert de la lysine, ARN de transfert de la phénylalanine, ARN de transfert du tryptophane, ARN de transfert spécifiques des différents acides aminés, Pancreatic ribonuclease, Ribonuclease T1.
- Données de séquences moléculaires, Inhibiteurs de la transcriptase inverse, Protéines recombinantes, Séquence nucléotidique.
English descriptors
- KwdEn :
- Base Sequence, DNA (biosynthesis), DNA Polymerase II (antagonists & inhibitors), HIV (enzymology), Molecular Sequence Data, RNA, Transfer, Amino Acid-Specific (pharmacology), RNA, Transfer, Lys (pharmacology), RNA, Transfer, Phe (pharmacology), RNA, Transfer, Trp (pharmacology), Recombinant Proteins, Reverse Transcriptase Inhibitors, Ribonuclease T1 (pharmacology), Ribonuclease, Pancreatic (pharmacology).
- MESH :
- chemical , antagonists & inhibitors : DNA Polymerase II.
- chemical , biosynthesis : DNA.
- enzymology : HIV.
- chemical , pharmacology : RNA, Transfer, Amino Acid-Specific, RNA, Transfer, Lys, RNA, Transfer, Phe, RNA, Transfer, Trp, Ribonuclease T1, Ribonuclease, Pancreatic.
- Base Sequence, Molecular Sequence Data, Recombinant Proteins, Reverse Transcriptase Inhibitors.
Abstract
Human immunodeficiency virus (HIV) reverse transcriptase (RT) uses host tRNA(Lys) partially annealed to the primer binding site (PBS) as primer for the initiation of cDNA synthesis. When assaying cDNA synthesis with a template-primer complex formed by an RNA fragment carrying the PBS site and bovine tRNA(Lys) we noticed that an excess of primer tRNA inhibited strongly the DNA polymerase activity of a recombinant HIV RT (p66-p51 heterodimeric form) produced in transformed yeast cells. The same inhibitory effect was observed with animal DNA polymerase alpha, while avian retrovirus RT was neither affected by tRNA(Lys) nor by its specific primer tRNA(Trp). Although the strongest inhibition was observed with tRNA(Lys), other tRNas like tRNA(Phe) and tRNA(Trp) inhibited also the HIV RT, whereas tRNAs specific for valine, proline and glycine had no effect on enzyme activity. Digestion of tRNA(Lys) with pancreatic RNase abolished the inhibition; on the other hand T1 RNase digestion had no effect on the inhibition suggesting a role of the anticodon region in this effect. The 12- and 14-mers corresponding to the anticodon regions of the three bovine tRNA(Lys) isoacceptors inhibited RT activity, indicating that at least an important part of the inhibitory effect could be ascribed to this tRNA region. A strong stimulation of DNA polymerase activity was observed when the effect of tRNA(Lys) was assayed on a recombinant HIV reverse transcriptase produced in a protease deficient yeast strain, which leads to the production of an active p66 enzyme. The same tRNAs that inhibited strongly the heterodimeric form stimulated the p66 form of HIV reverse transcriptase. The results suggest that although both enzymatic forms are able to interact with tRNA(Lys) the topography, as well as the functional implications of the interaction between the precursor and the mature form of HIV reverse transcriptase with the tRNA(Lys) primer, are different.
DOI: 10.1093/nar/18.3.429
PubMed: 1689823
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:1689823Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inhibition of the p66/p51 form of human immunodeficiency virus reverse transcriptase by tRNA(Lys).</title>
<author><name sortKey="Bordier, B" sort="Bordier, B" uniqKey="Bordier B" first="B" last="Bordier">B. Bordier</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut de Biochimie Cellulaire et Neurochimie du CNRS, Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Biochimie Cellulaire et Neurochimie du CNRS, Bordeaux</wicri:regionArea>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tarrago Litvak, L" sort="Tarrago Litvak, L" uniqKey="Tarrago Litvak L" first="L" last="Tarrago-Litvak">L. Tarrago-Litvak</name>
</author>
<author><name sortKey="Sallafranque Andreola, M L" sort="Sallafranque Andreola, M L" uniqKey="Sallafranque Andreola M" first="M L" last="Sallafranque-Andreola">M L Sallafranque-Andreola</name>
</author>
<author><name sortKey="Robert, D" sort="Robert, D" uniqKey="Robert D" first="D" last="Robert">D. Robert</name>
</author>
<author><name sortKey="Tharaud, D" sort="Tharaud, D" uniqKey="Tharaud D" first="D" last="Tharaud">D. Tharaud</name>
</author>
<author><name sortKey="Fournier, M" sort="Fournier, M" uniqKey="Fournier M" first="M" last="Fournier">M. Fournier</name>
</author>
<author><name sortKey="Barr, P J" sort="Barr, P J" uniqKey="Barr P" first="P J" last="Barr">P J Barr</name>
</author>
<author><name sortKey="Litvak, S" sort="Litvak, S" uniqKey="Litvak S" first="S" last="Litvak">S. Litvak</name>
</author>
<author><name sortKey="Sarih Cottin, L" sort="Sarih Cottin, L" uniqKey="Sarih Cottin L" first="L" last="Sarih-Cottin">L. Sarih-Cottin</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1990">1990</date>
<idno type="RBID">pubmed:1689823</idno>
<idno type="pmid">1689823</idno>
<idno type="doi">10.1093/nar/18.3.429</idno>
<idno type="wicri:Area/PubMed/Corpus">002A28</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A28</idno>
<idno type="wicri:Area/PubMed/Curation">002A28</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002A28</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002864</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002864</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Inhibition of the p66/p51 form of human immunodeficiency virus reverse transcriptase by tRNA(Lys).</title>
<author><name sortKey="Bordier, B" sort="Bordier, B" uniqKey="Bordier B" first="B" last="Bordier">B. Bordier</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut de Biochimie Cellulaire et Neurochimie du CNRS, Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Biochimie Cellulaire et Neurochimie du CNRS, Bordeaux</wicri:regionArea>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tarrago Litvak, L" sort="Tarrago Litvak, L" uniqKey="Tarrago Litvak L" first="L" last="Tarrago-Litvak">L. Tarrago-Litvak</name>
</author>
<author><name sortKey="Sallafranque Andreola, M L" sort="Sallafranque Andreola, M L" uniqKey="Sallafranque Andreola M" first="M L" last="Sallafranque-Andreola">M L Sallafranque-Andreola</name>
</author>
<author><name sortKey="Robert, D" sort="Robert, D" uniqKey="Robert D" first="D" last="Robert">D. Robert</name>
</author>
<author><name sortKey="Tharaud, D" sort="Tharaud, D" uniqKey="Tharaud D" first="D" last="Tharaud">D. Tharaud</name>
</author>
<author><name sortKey="Fournier, M" sort="Fournier, M" uniqKey="Fournier M" first="M" last="Fournier">M. Fournier</name>
</author>
<author><name sortKey="Barr, P J" sort="Barr, P J" uniqKey="Barr P" first="P J" last="Barr">P J Barr</name>
</author>
<author><name sortKey="Litvak, S" sort="Litvak, S" uniqKey="Litvak S" first="S" last="Litvak">S. Litvak</name>
</author>
<author><name sortKey="Sarih Cottin, L" sort="Sarih Cottin, L" uniqKey="Sarih Cottin L" first="L" last="Sarih-Cottin">L. Sarih-Cottin</name>
</author>
</analytic>
<series><title level="j">Nucleic acids research</title>
<idno type="ISSN">0305-1048</idno>
<imprint><date when="1990" type="published">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Base Sequence</term>
<term>DNA (biosynthesis)</term>
<term>DNA Polymerase II (antagonists & inhibitors)</term>
<term>HIV (enzymology)</term>
<term>Molecular Sequence Data</term>
<term>RNA, Transfer, Amino Acid-Specific (pharmacology)</term>
<term>RNA, Transfer, Lys (pharmacology)</term>
<term>RNA, Transfer, Phe (pharmacology)</term>
<term>RNA, Transfer, Trp (pharmacology)</term>
<term>Recombinant Proteins</term>
<term>Reverse Transcriptase Inhibitors</term>
<term>Ribonuclease T1 (pharmacology)</term>
<term>Ribonuclease, Pancreatic (pharmacology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ADN (biosynthèse)</term>
<term>ARN de transfert de la lysine (pharmacologie)</term>
<term>ARN de transfert de la phénylalanine (pharmacologie)</term>
<term>ARN de transfert du tryptophane (pharmacologie)</term>
<term>ARN de transfert spécifiques des différents acides aminés (pharmacologie)</term>
<term>DNA polymerase II (antagonistes et inhibiteurs)</term>
<term>Données de séquences moléculaires</term>
<term>Inhibiteurs de la transcriptase inverse</term>
<term>Pancreatic ribonuclease (pharmacologie)</term>
<term>Protéines recombinantes</term>
<term>Ribonuclease T1 (pharmacologie)</term>
<term>Séquence nucléotidique</term>
<term>VIH (Virus de l'Immunodéficience Humaine) (enzymologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>DNA Polymerase II</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>DNA</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>DNA polymerase II</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>ADN</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>VIH (Virus de l'Immunodéficience Humaine)</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>HIV</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>ARN de transfert de la lysine</term>
<term>ARN de transfert de la phénylalanine</term>
<term>ARN de transfert du tryptophane</term>
<term>ARN de transfert spécifiques des différents acides aminés</term>
<term>Pancreatic ribonuclease</term>
<term>Ribonuclease T1</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>RNA, Transfer, Amino Acid-Specific</term>
<term>RNA, Transfer, Lys</term>
<term>RNA, Transfer, Phe</term>
<term>RNA, Transfer, Trp</term>
<term>Ribonuclease T1</term>
<term>Ribonuclease, Pancreatic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Base Sequence</term>
<term>Molecular Sequence Data</term>
<term>Recombinant Proteins</term>
<term>Reverse Transcriptase Inhibitors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Données de séquences moléculaires</term>
<term>Inhibiteurs de la transcriptase inverse</term>
<term>Protéines recombinantes</term>
<term>Séquence nucléotidique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Human immunodeficiency virus (HIV) reverse transcriptase (RT) uses host tRNA(Lys) partially annealed to the primer binding site (PBS) as primer for the initiation of cDNA synthesis. When assaying cDNA synthesis with a template-primer complex formed by an RNA fragment carrying the PBS site and bovine tRNA(Lys) we noticed that an excess of primer tRNA inhibited strongly the DNA polymerase activity of a recombinant HIV RT (p66-p51 heterodimeric form) produced in transformed yeast cells. The same inhibitory effect was observed with animal DNA polymerase alpha, while avian retrovirus RT was neither affected by tRNA(Lys) nor by its specific primer tRNA(Trp). Although the strongest inhibition was observed with tRNA(Lys), other tRNas like tRNA(Phe) and tRNA(Trp) inhibited also the HIV RT, whereas tRNAs specific for valine, proline and glycine had no effect on enzyme activity. Digestion of tRNA(Lys) with pancreatic RNase abolished the inhibition; on the other hand T1 RNase digestion had no effect on the inhibition suggesting a role of the anticodon region in this effect. The 12- and 14-mers corresponding to the anticodon regions of the three bovine tRNA(Lys) isoacceptors inhibited RT activity, indicating that at least an important part of the inhibitory effect could be ascribed to this tRNA region. A strong stimulation of DNA polymerase activity was observed when the effect of tRNA(Lys) was assayed on a recombinant HIV reverse transcriptase produced in a protease deficient yeast strain, which leads to the production of an active p66 enzyme. The same tRNAs that inhibited strongly the heterodimeric form stimulated the p66 form of HIV reverse transcriptase. The results suggest that although both enzymatic forms are able to interact with tRNA(Lys) the topography, as well as the functional implications of the interaction between the precursor and the mature form of HIV reverse transcriptase with the tRNA(Lys) primer, are different.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1689823</PMID>
<DateCompleted><Year>1990</Year>
<Month>04</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>05</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0305-1048</ISSN>
<JournalIssue CitedMedium="Print"><Volume>18</Volume>
<Issue>3</Issue>
<PubDate><Year>1990</Year>
<Month>Feb</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Nucleic acids research</Title>
<ISOAbbreviation>Nucleic Acids Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of the p66/p51 form of human immunodeficiency virus reverse transcriptase by tRNA(Lys).</ArticleTitle>
<Pagination><MedlinePgn>429-36</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Human immunodeficiency virus (HIV) reverse transcriptase (RT) uses host tRNA(Lys) partially annealed to the primer binding site (PBS) as primer for the initiation of cDNA synthesis. When assaying cDNA synthesis with a template-primer complex formed by an RNA fragment carrying the PBS site and bovine tRNA(Lys) we noticed that an excess of primer tRNA inhibited strongly the DNA polymerase activity of a recombinant HIV RT (p66-p51 heterodimeric form) produced in transformed yeast cells. The same inhibitory effect was observed with animal DNA polymerase alpha, while avian retrovirus RT was neither affected by tRNA(Lys) nor by its specific primer tRNA(Trp). Although the strongest inhibition was observed with tRNA(Lys), other tRNas like tRNA(Phe) and tRNA(Trp) inhibited also the HIV RT, whereas tRNAs specific for valine, proline and glycine had no effect on enzyme activity. Digestion of tRNA(Lys) with pancreatic RNase abolished the inhibition; on the other hand T1 RNase digestion had no effect on the inhibition suggesting a role of the anticodon region in this effect. The 12- and 14-mers corresponding to the anticodon regions of the three bovine tRNA(Lys) isoacceptors inhibited RT activity, indicating that at least an important part of the inhibitory effect could be ascribed to this tRNA region. A strong stimulation of DNA polymerase activity was observed when the effect of tRNA(Lys) was assayed on a recombinant HIV reverse transcriptase produced in a protease deficient yeast strain, which leads to the production of an active p66 enzyme. The same tRNAs that inhibited strongly the heterodimeric form stimulated the p66 form of HIV reverse transcriptase. The results suggest that although both enzymatic forms are able to interact with tRNA(Lys) the topography, as well as the functional implications of the interaction between the precursor and the mature form of HIV reverse transcriptase with the tRNA(Lys) primer, are different.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bordier</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Institut de Biochimie Cellulaire et Neurochimie du CNRS, Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tarrago-Litvak</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sallafranque-Andreola</LastName>
<ForeName>M L</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y"><LastName>Robert</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tharaud</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fournier</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Barr</LastName>
<ForeName>P J</ForeName>
<Initials>PJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Litvak</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sarih-Cottin</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Nucleic Acids Res</MedlineTA>
<NlmUniqueID>0411011</NlmUniqueID>
<ISSNLinking>0305-1048</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012345">RNA, Transfer, Amino Acid-Specific</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012357">RNA, Transfer, Lys</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012360">RNA, Transfer, Phe</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012364">RNA, Transfer, Trp</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9007-49-2</RegistryNumber>
<NameOfSubstance UI="D004247">DNA</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber>
<NameOfSubstance UI="D004257">DNA Polymerase II</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.1.27.3</RegistryNumber>
<NameOfSubstance UI="D006163">Ribonuclease T1</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.1.27.5</RegistryNumber>
<NameOfSubstance UI="D012259">Ribonuclease, Pancreatic</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CitationSubset>X</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004257" MajorTopicYN="N">DNA Polymerase II</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006678" MajorTopicYN="N">HIV</DescriptorName>
<QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012345" MajorTopicYN="N">RNA, Transfer, Amino Acid-Specific</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012357" MajorTopicYN="N">RNA, Transfer, Lys</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012360" MajorTopicYN="N">RNA, Transfer, Phe</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012364" MajorTopicYN="N">RNA, Transfer, Trp</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018894" MajorTopicYN="Y">Reverse Transcriptase Inhibitors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006163" MajorTopicYN="N">Ribonuclease T1</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012259" MajorTopicYN="N">Ribonuclease, Pancreatic</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year>
<Month>2</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1990</Year>
<Month>2</Month>
<Day>11</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1990</Year>
<Month>2</Month>
<Day>11</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">1689823</ArticleId>
<ArticleId IdType="pmc">PMC333444</ArticleId>
<ArticleId IdType="doi">10.1093/nar/18.3.429</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Biochemistry. 1988 Dec 13;27(25):8884-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2466481</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1970 Aug 15;227(5259):680-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5432063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 1989 Nov;8(11):3279-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2479543</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Biochem. 1989 Sep 15;184(2):367-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2477248</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biochem. 1989 Jun;105(6):974-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2475486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 1985 Jan;40(1):9-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2981635</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1988 Jun 10;240(4858):1427-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3287617</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1989 Apr 25;264(12):7073-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2468665</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1989 May;86(10):3539-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2471188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 1988 Jan;7(1):239-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2452083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEBS Lett. 1988 Mar 28;230(1-2):61-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2450786</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1986 Nov;60(2):771-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2430111</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1987 Apr 17;236(4799):305-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2436298</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1986 Sep;59(3):743-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2426471</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1985 Feb 1;227(4686):484-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2578227</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 1988 Jun 10;16(11):5153-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3387221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anal Biochem. 1983 Oct 1;134(1):184-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6197900</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1983 May 20;220(4599):868-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6189183</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anal Biochem. 1982 Jan 1;119(1):142-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7072935</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods Enzymol. 1981;73(Pt B):46-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7300686</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Biochem. 1979 Jun;97(1):305-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">225173</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochim Biophys Acta. 1977 Mar 21;473(1):1-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">66065</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1976 Nov;75(1):26-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">62451</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1979 Nov 10;254(21):10979-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">115865</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochimie. 1976;58(10):1159-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1009171</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochemistry. 1969 Mar;8(3):832-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5781021</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1975 Jul;72(7):2535-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">52156</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1975 May 10;250(9):3487-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">164470</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 1988 Jun;7(6):1777-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2458920</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Aquitaine</li>
<li>Nouvelle-Aquitaine</li>
</region>
<settlement><li>Bordeaux</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Barr, P J" sort="Barr, P J" uniqKey="Barr P" first="P J" last="Barr">P J Barr</name>
<name sortKey="Fournier, M" sort="Fournier, M" uniqKey="Fournier M" first="M" last="Fournier">M. Fournier</name>
<name sortKey="Litvak, S" sort="Litvak, S" uniqKey="Litvak S" first="S" last="Litvak">S. Litvak</name>
<name sortKey="Robert, D" sort="Robert, D" uniqKey="Robert D" first="D" last="Robert">D. Robert</name>
<name sortKey="Sallafranque Andreola, M L" sort="Sallafranque Andreola, M L" uniqKey="Sallafranque Andreola M" first="M L" last="Sallafranque-Andreola">M L Sallafranque-Andreola</name>
<name sortKey="Sarih Cottin, L" sort="Sarih Cottin, L" uniqKey="Sarih Cottin L" first="L" last="Sarih-Cottin">L. Sarih-Cottin</name>
<name sortKey="Tarrago Litvak, L" sort="Tarrago Litvak, L" uniqKey="Tarrago Litvak L" first="L" last="Tarrago-Litvak">L. Tarrago-Litvak</name>
<name sortKey="Tharaud, D" sort="Tharaud, D" uniqKey="Tharaud D" first="D" last="Tharaud">D. Tharaud</name>
</noCountry>
<country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Bordier, B" sort="Bordier, B" uniqKey="Bordier B" first="B" last="Bordier">B. Bordier</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002864 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002864 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:1689823 |texte= Inhibition of the p66/p51 form of human immunodeficiency virus reverse transcriptase by tRNA(Lys). }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:1689823" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |